Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation
Language English Country France Media print-electronic
Document type Journal Article
PubMed
27721153
DOI
10.1016/j.ejmech.2016.09.078
PII: S0223-5234(16)30816-9
Knihovny.cz E-resources
- Keywords
- Acetylcholinesterase inhibitors, Alzheimer's disease, Aβ aggregation, BACE1 inhibitors, Molecular docking, Multifunctional agents,
- MeSH
- Amines chemistry pharmacology MeSH
- Amyloid beta-Peptides metabolism MeSH
- Cholinesterases metabolism MeSH
- Phthalimides chemical synthesis chemistry pharmacology MeSH
- Blood-Brain Barrier drug effects MeSH
- Inhibitory Concentration 50 MeSH
- Enzyme Inhibitors chemical synthesis chemistry pharmacology MeSH
- Drug Delivery Systems MeSH
- Humans MeSH
- Molecular Structure MeSH
- Protein Aggregation, Pathological MeSH
- Peptide Fragments metabolism MeSH
- Drug Design MeSH
- Saccharin chemical synthesis chemistry pharmacology MeSH
- Amyloid Precursor Protein Secretases metabolism MeSH
- Protein Binding drug effects MeSH
- Binding Sites MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Amines MeSH
- amyloid beta-protein (1-34) MeSH Browser
- Amyloid beta-Peptides MeSH
- Cholinesterases MeSH
- Phthalimides MeSH
- Enzyme Inhibitors MeSH
- Peptide Fragments MeSH
- phthalimide MeSH Browser
- Saccharin MeSH
- Amyloid Precursor Protein Secretases MeSH
The complexity of Alzheimer's disease (AD) calls for search of multifunctional compounds as potential candidates for effective therapy. A series of phthalimide and saccharin derivatives linked by different alicyclic fragments (piperazine, hexahydropyrimidine, 3-aminopyrrolidine or 3-aminopiperidine) with phenylalkyl moieties attached have been designed, synthesized, and evaluated as multifunctional anti-AD agents with cholinesterase, β-secretase and β-amyloid inhibitory activities. In vitro studies showed that the majority of saccharin derivatives with piperazine moiety and one phthalimide derivative with 3-aminopiperidine fragment exhibited inhibitory potency toward acetylcholinesterase (AChE) with EeAChE IC50 values ranging from 0.83 μM to 19.18 μM. The target compounds displayed inhibition of human β-secretase-1 (hBACE1) ranging from 26.71% to 61.42% at 50 μM concentration. Among these compounds, two multifunctional agents (26, [2-(2-(4-benzylpiperazin-1-yl)ethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide] and 52, 2-(2-(3-(3,5-difluorobenzylamino)piperidin-1-yl)ethyl)isoindoline-1,3-dione) have been identified. Compound 26 exhibited the highest inhibitory potency against EeAChE (IC50 = 0.83 μM) and inhibitory activity against hBACE1 (33.61% at 50 μM). Compound 52 is a selective AChE inhibitor (IC50 AChE = 6.47 μM) with BACE1 inhibitory activity (26.3% at 50 μM) and it displays the most significant Aβ anti-aggregating properties among all the obtained compounds (39% at 10 μM). Kinetic and molecular modeling studies indicate that 26 may act as non-competitive AChE inhibitor able to interact with both catalytic and peripheral active site of the enzyme.
References provided by Crossref.org
Exploring Phthalimide as the Acid Component in the Passerini Reaction
Profiling donepezil template into multipotent hybrids with antioxidant properties
Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy